This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E34.8 (Other specified endocrine disorders — Pineal gland dysfunction) | Special Copayment Reduction: V166 (rare disease) | ※ Progeria also has the same ICD-10 code but is a separate disease. |
| B. Synonyms | Pineal body dysfunction, abnormal melatonin secretion, Pinealoma-related endocrinopathy, Pineal region tumor endocrine dysfunction |
| C. Adult onset | Adult onset possible — pineal tumors are common from childhood to early adulthood but can occur at any age. Abnormal melatonin secretion also presents in adults as sleep disorders and circadian rhythm disorders. |
| 1. History | Descartes' 'seat of the soul' → 1917: discovery of melatonin by Carey and McCord → 1958: structure determined by Lerner → 1980s: mechanism of circadian rhythm regulation established → endocrine effects of pineal tumors described. |
| 2. Causes | Pineal tumors (germinoma, pineocytoma, pineoblastoma, astrocytoma), pineal cysts, destruction by compression/infiltration, abnormalities of melatonin-synthesizing enzymes, insufficiency after surgery/radiation. |
| 3. Genetics | Mostly non-hereditary, sporadic occurrence. Pineoblastoma: associated with RB1, DICER1, and BRCA2 variants. Germinoma: KIT and KRAS variants. Polymorphisms in genes for melatonin synthesis-related enzymes are associated with some functional abnormalities. |
| 4. General epidemiology | Pineal tumors account for 0.4–1% of intracranial tumors and 3–8% of pediatric intracranial tumors. Germinoma is more frequent in East Asia (Korea, Japan, China) than in Western countries. Slightly more common in males. |
| 5. Pathophysiology | Decreased melatonin secretion → circadian rhythm disorders. Compression/infiltration of the hypothalamus and pituitary by the tumor → precocious puberty (release of GnRH regulation), diabetes insipidus (decreased ADH), growth hormone abnormalities. Compression of the cerebral aqueduct → hydrocephalus. |
| 6. Symptoms | Headache, nausea, vomiting (hydrocephalus), visual disturbances (Parinaud syndrome: upward gaze palsy), precocious puberty (children), diabetes insipidus, sleep-wake rhythm disorders, growth failure. |
| 7. Signs | Parinaud syndrome (vertical gaze palsy, convergence-retraction nystagmus, pupillary abnormalities). Signs of increased intracranial pressure. Findings of early puberty (children). Abnormalities in serum βhCG, AFP, melatonin, and serum LH/FSH. |
| 8. Screening | Brain MRI in children with precocious puberty, diabetes insipidus, or visual disturbances. Serum tumor markers (βhCG, AFP). Nocturnal urinary melatonin or plasma melatonin (circadian rhythm evaluation). |
| 9. Diagnosis | Brain MRI (contrast-enhanced). Serum and cerebrospinal fluid βhCG/AFP. Ophthalmologic examination (Parinaud). Cerebrospinal fluid cytology. Tissue biopsy (stereotactic surgery or endoscopy). Hormone profile (LH/FSH, cortisol, IGF-1, ADH). |
| 10. Treatment | Germinoma: radiation alone or chemotherapy + radiation (survival over 90%). Non-germinomatous germ cell tumors: surgery + chemotherapy + radiation. Pineocytoma: surgical resection. Hydrocephalus: endoscopic third ventriculostomy (ETV). Hormone replacement: diabetes insipidus (desmopressin), precocious puberty (GnRH analogues). Melatonin supplementation (in functional insufficiency). |
| 11. Prognosis | Germinoma 5-year survival 90–95%. Pineoblastoma has a poor prognosis (5-year survival 50–60%). Hormonal sequelae (diabetes insipidus, growth failure, hypogonadism) may be permanent. |
| 12. Prevention | No primary prevention (sporadic tumors). Early detection and monitoring of hormonal function. Regular follow-up of growth and endocrine function after treatment. Sleep hygiene education related to nocturnal melatonin. |
| 13. References | Balmaceda C et al. Chemotherapy without irradiation (1996) and 9 others |
The history of the pineal gland (pineal body) goes back more than 2,000 years. The ancient Greek physician Galen (Galenus, 2nd century) described this small pine cone-shaped structure as 'a valve regulating the flow of cerebrospinal fluid', and in the 17th century the French philosopher René Descartes identified this organ, which is single unlike the paired cerebral hemispheres, as the 'seat of the soul'. Descartes believed that the pineal gland served to integrate information from the left and right hemispheres, and this concept long remained a subject of philosophical debate. Of course, this was philosophical speculation without scientific basis, but paradoxically it sustained interest in this organ.
Scientific research began in earnest in the 20th century. In 1917, the American researchers Carey and McCord observed that treating tadpole skin with bovine pineal extract lightened the skin, and they named this active substance 'melatonin'. In 1958, Aaron Lerner and colleagues isolated pure melatonin from bovine pineal glands and determined its chemical structure (N-acetyl-5-methoxytryptamine) (PMID: 13554900). This revealed melatonin to be a neuroendocrine hormone of the indoleamine class, and the synthetic pathway leading from tryptophan to serotonin to melatonin was subsequently elucidated step by step.
From the 1970s onward, the mechanism by which melatonin secretion is regulated by the light-dark cycle was elucidated. It was established that light signals are transmitted from retinal photoreceptors via the retinohypothalamic tract to the suprachiasmatic nucleus (SCN); the SCN, via the paraventricular nucleus, regulates sympathetic preganglionic neurons of the intermediolateral cell column of the spinal cord; and this signal is relayed through the superior cervical ganglion to the pineal gland, where increased norepinephrine release at night promotes melatonin synthesis. This confirmed that the pineal gland is not merely a 'vestigial organ' but plays a key role in regulating circadian rhythms.
In terms of clinical endocrinology, it had been known through clinical case reports in the late 19th to early 20th century that pineal tumors occurring in children cause central precocious puberty or delayed sexual development. In particular, Heubner first described the association between pineal tumors and precocious puberty in 1898, and later, as the physiological role of melatonin in suppressing hypothalamic GnRH secretion was revealed, the mechanism by which melatonin deficiency can cause precocious puberty through loss of GnRH suppression came to be understood. In ICD-10, E34.8 is a code covering other specified endocrine disorders, and pineal gland dysfunction (abnormal melatonin secretion and tumor-related endocrine effects) is classified under this code.
The most important cause of pineal gland dysfunction is pineal region tumors. Tumors arising in this region are broadly divided into germ cell tumors and pineal parenchymal tumors. Among germ cell tumors, germinoma is the most common and is a tumor with a good prognosis that responds very well to radiation therapy alone or combined chemoradiation therapy. Non-germinomatous germ cell tumors (NGGCT) include embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma, and mixed types, and their prognoses vary.
Pineal parenchymal tumors include pineocytoma (WHO grade I–II) and pineoblastoma (WHO grade IV). Pineocytoma has a relatively benign course and can be cured by surgical resection, whereas pineoblastoma is very aggressive and may cause cerebrospinal fluid dissemination (CSF seeding). Other tumors, such as astrocytoma, ependymoma, and meningioma, can also arise in the pineal region and cause dysfunction. Pineal cysts are very common (about 1–4% of the general population) and mostly asymptomatic, but depending on size or location they can cause hydrocephalus.
Causes other than tumors include damage to pineal tissue after cranial radiation therapy, pineal insufficiency after surgical resection, destruction of pineal tissue by hypoxia or trauma, and reduced function due to endocrine or autoimmune mechanisms. Functional abnormalities related to melatonin-synthesizing enzymes (arylalkylamine N-acetyltransferase, AANAT; hydroxyindole-O-methyltransferase, HIOMT) may also be associated with some sleep disorders and circadian rhythm disorders. Physiological aging, in which the pineal gland calcifies and melatonin secretion decreases with age, is also a cause of reduced function and is related to the increase in sleep disorders in the elderly.
Most pineal tumors are sporadic, and associations with specific genetic syndromes are limited to a few. Pineoblastoma is associated with hereditary retinoblastoma (RB1 variants) and can occur in the form of 'trilateral retinoblastoma', which refers to the development in children of a primitive neuroectodermal tumor (PNET) of the pineal or retro-orbital region simultaneously with or after bilateral retinoblastoma. Recently, DICER1 gene variants have been reported to be associated with some pineoblastomas, and an association with BRCA2 variants has also been described at the level of case reports.
In germinoma, KIT gene variants (c.816K→E/V, gain-of-function mutations) and KRAS variants have been reported, which are related to abnormal migration and proliferation of pluripotent germ cells. Central nervous system germinoma has been reported to be associated with congenital immunodeficiency or Klinefelter syndrome (47,XXY), so the risk may be increased in carriers of XY chromosomal abnormalities. Polymorphisms in genes related to melatonin synthesis and receptors (e.g., the MTNR1A and MTNR1B receptor genes and the AANAT gene) have been suggested through genome-wide association studies (GWAS) to be associated with sleep disorders, seasonal affective disorder, and some metabolic diseases, but these do not directly fall under the diagnostic criteria for 'pineal gland dysfunction'.
Pineal region tumors account for about 0.4–1% of all intracranial tumors and show a relatively high proportion in children, about 3–8% of all intracranial tumors. A notable point in the geographic and ethnic distribution is that the frequency of central nervous system germinoma is markedly higher in East Asia (Japan, Korea, China) than in Western countries. According to Japanese data, germinoma accounts for about 2–3% of all intracranial tumors, 4–5 times higher than the 0.5–0.6% in Western countries. In Korea, too, germinoma accounts for a considerable proportion of brain tumors in children and adolescents, and this ethnic difference is presumed to reflect specific genetic predispositions or population differences in genes related to germ cell migration.
In terms of age of onset, germ cell tumors are concentrated in the teens and twenties, pineocytoma occurs mainly in middle adulthood, and pineoblastoma mainly in childhood (mean age around 8 years). The male-to-female ratio for germinoma is about 2–3:1, more common in males, but the proportion of females is higher for germinomas around the pituitary. Accurate epidemiological data on the prevalence of pure melatonin secretory dysfunction (melatonin deficiency or excess without a tumor) are lacking; melatonin abnormalities are very common in the population with sleep disorders, but cases with an organic pineal lesion warranting classification as E34.8 are rare.
The main function of the pineal gland is the synthesis and secretion of melatonin. Normally at night, under SCN control, sympathetic activation → stimulation of β-adrenergic receptors on pineal cells → increased cAMP → activation of arylalkylamine N-acetyltransferase (AANAT) → activation of the serotonin–N-acetylserotonin–melatonin synthesis pathway. Melatonin secretion is immediately suppressed by light exposure (blocking of SCN signals by light), thereby providing the whole body with biological clock signals matched to the day-night cycle. When pineal function is lost due to a tumor or destruction, nocturnal melatonin secretion decreases, resulting in circadian rhythm disorders and disruption of the sleep-wake cycle.
Pineal region tumors cause endocrine abnormalities through direct hormone secretion or compression of adjacent structures. Some germinomas and non-germinomatous tumors secrete human chorionic gonadotropin (βhCG) and can cause central precocious puberty. βhCG has an LH-like action and stimulates testicular Leydig cells, leading to excessive testosterone secretion → precocious puberty in young boys. In girls, precocious puberty due to this mechanism is rare, which is presumed to be because ovarian LH/hCG receptors are less sensitive than Leydig cells.
Because melatonin acts to suppress pulsatile GnRH secretion at the level of the hypothalamic SCN, melatonin deficiency due to destruction or loss of function of the pineal gland can lead to loss of suppression of hypothalamic GnRH secretion and cause early sexual maturation. Conversely, in states of excess melatonin secretion, the hypothalamic-pituitary-gonadal axis is suppressed and delayed sexual development may appear. When a tumor compresses the cerebral aqueduct (aqueduct of Sylvius), obstructive hydrocephalus develops, and when it compresses the dorsal midbrain, Parinaud syndrome (upward gaze palsy, convergence-retraction nystagmus, impaired pupillary light reflex) appears. With infiltration of hypothalamic or pituitary lesions, diabetes insipidus (decreased antidiuretic hormone, ADH, secretion), growth hormone deficiency, and panhypopituitarism may occur.
The most common symptoms of pineal region tumors are symptoms of increased intracranial pressure due to obstructive hydrocephalus. Headache is the most common chief complaint and tends to be worse in the morning and accompanied by nausea and vomiting. Headache is intermittent at first but becomes persistent as the tumor grows. As hydrocephalus worsens, clouding of consciousness, irritability, memory impairment, and cognitive decline may appear, and if not treated properly it can lead to fatal brain herniation (transtentorial herniation). Visual symptoms include diplopia (double vision on upward gaze), decreased visual acuity, and abnormal eye movements, and Parinaud syndrome (upward gaze palsy, convergence-retraction nystagmus) is characteristic.
Precocious puberty due to βhCG-secreting tumors arising in children is the main endocrine symptom. In young boys, increased testicular volume, appearance of pubic hair, penile enlargement, acne, and rapid growth may appear, which are findings of precocious puberty early for their age. In this case, LH/FSH are at low prepubertal levels, but because βhCG stimulates LH receptors, it presents as 'peripheral (gonadotropin-independent) precocious puberty'. Diabetes insipidus occurs with hypothalamic or pituitary infiltration and presents with polyuria, polydipsia, and nocturia. Growth failure occurs due to growth hormone deficiency or as a sequela of cranial radiation therapy.
In melatonin secretory dysfunction (reduced pineal function without a tumor), difficulty falling asleep, difficulty maintaining sleep, advanced or delayed sleep-wake cycles, and symptoms of seasonal affective disorder (SAD) may appear. Sleep disorders due to suppression of melatonin secretion in shift workers or people with heavy nighttime light exposure may also be managed in this category.
Parinaud syndrome (dorsal midbrain syndrome) is a characteristic neuro-ophthalmological syndrome caused by compression of the dorsal midbrain, with three cardinal signs: upward gaze palsy, convergence-retraction nystagmus, and impaired pupillary light reflex (light-near dissociation). These signs are nearly specific to pineal region tumors, so immediate brain imaging is required when they are found. When intracranial pressure is increased, papilledema is identified on fundoscopic examination, and in advanced cases decreased visual acuity and visual field defects are present.
In βhCG-secreting tumors, serum and cerebrospinal fluid βhCG are markedly elevated (normal <5mIU/mL), which has not only diagnostic value but is also used as a biomarker for tracking treatment response and recurrence. Serum AFP is elevated in yolk sac tumors. In precocious puberty, serum testosterone or estradiol is elevated for age, but LH/FSH are low (peripheral pattern), so differentiation from hypothalamic precocious puberty is needed. Diabetes insipidus is characterized by polyuria, dilute urine (urine osmolality <300mOsm/kg), hypernatremia, elevated plasma osmolality, and low blood ADH, and is confirmed by the water deprivation test and the DDAVP response test.
Normally, serum melatonin shows a marked difference between night (peak at 2–4 a.m.) and day (lowest), and with reduced pineal function the nocturnal peak decreases. In clinical practice, measurement of nocturnal urinary 6-sulphatoxymelatonin (a melatonin metabolite) is more practical than measuring serum melatonin.
Screening of the general population for pineal gland dysfunction is not recommended. Immediate screening is needed in the following clinical situations. First, precocious puberty in children: brain MRI and measurement of serum βhCG/AFP are essential in children with secondary sexual characteristics early for their age (especially boys with peripheral precocious puberty with elevated testosterone without elevated LH/FSH). Second, findings of Parinaud syndrome: when upward gaze palsy and convergence-retraction nystagmus are identified, brain MRI is performed immediately. Third, findings of increased intracranial pressure (idiopathic headache, nausea, vomiting, and papilledema): especially in children and adolescents with this symptom complex, imaging should be performed first to screen for tumors.
In patients with sleep disorders or circadian rhythm disorders, melatonin secretory function is evaluated by serial nighttime (10 p.m.–6 a.m.) serum melatonin sampling or measurement of nocturnal urinary 6-sulphatoxymelatonin. The onset time of serum melatonin measured under light-shielded conditions (dim light melatonin onset, DLMO) is used as the standard for assessing circadian phase. This test can also be applied in elderly patients with sleep disorders in whom melatonin deficiency is suspected, but this falls under the category of physiological aging rather than pineal gland dysfunction in the strict sense.
Brain MRI (contrast-enhanced) is the key test for diagnosing pineal region tumors. It is performed with a standard protocol including T1, T2, FLAIR, and contrast-enhanced T1 sequences, evaluating the size, location, and enhancement pattern of the tumor and involvement of surrounding structures (aqueduct, thalamus, hypothalamus, pituitary). There are certain limits to predicting the histological type, but findings such as complex cystic structures, fat content, calcification, and hemorrhage aid diagnosis. MRI of the entire spine is also performed to evaluate cerebrospinal fluid dissemination. Brain CT is used as an adjunct to evaluate calcification and hemorrhage.
Serum and cerebrospinal fluid βhCG and AFP are important diagnostic markers of germ cell tumors. Elevated βhCG with normal AFP suggests germinoma or a mixed germ cell tumor (including a germinoma component), while elevated AFP suggests yolk sac tumor or the inclusion of a non-germinomatous component. In pure germinoma, βhCG is mildly elevated or normal, and AFP is normal. Cerebrospinal fluid cytology evaluates cerebrospinal fluid dissemination, and germ cell tumor cells may be detected. Histological diagnosis through stereotactic biopsy or neuroendoscopic biopsy is the standard for final confirmation. Pituitary function is evaluated with serum GH/IGF-1, cortisol/ACTH, LH/FSH/testosterone, thyroid function, and ADH/osmolality.
Germinoma is very sensitive to radiation and chemotherapy and is a tumor with a good prognosis, with a 5-year survival rate reaching 90–95% when properly treated. The current standard treatment recommended is the combined regimen of chemotherapy (carboplatin + etoposide or a cisplatin-based regimen) followed by irradiation (reduced-dose radiation: craniospinal or whole-brain irradiation + local boost), which is moving toward minimizing neurocognitive adverse effects by reducing the radiation field and dose compared with radiation alone. For localized germinoma without metastasis, local radiation + chemotherapy is often sufficient.
Non-germinomatous germ cell tumors (NGGCT) have a worse prognosis than germinoma, and the standard treatment is the combined regimen of surgical resection (when possible) + chemotherapy (BEP regimen: bleomycin, etoposide, cisplatin, etc.) + radiation. For pineocytoma (WHO grade I), complete surgical resection is the principle of treatment, and the prognosis is good with complete resection. When complete resection is not possible, radiation therapy is added. Pineoblastoma (WHO grade IV) is treated with combined chemoradiation therapy after surgery, but the prognosis is poor. For hydrocephalus, endoscopic third ventriculostomy (ETV) is the first-line treatment, and a ventriculoperitoneal shunt (VP shunt) is the alternative.
Diabetes insipidus: treated with desmopressin (DDAVP) nasal spray or oral formulations. Precocious puberty: pubertal progression is suppressed with GnRH analogues (leuprorelin, etc.). Growth hormone deficiency: when growth hormone deficiency is confirmed after radiation therapy, supplementation with recombinant growth hormone (rhGH). Panhypopituitarism: individual replacement therapy for the respective deficient hormones (thyroid, adrenal, gonadal). Melatonin insufficiency: improvement of the sleep-wake cycle may be attempted with exogenous melatonin (0.5–5mg, taken 30 minutes before bedtime) or a melatonin receptor agonist (ramelteon).
Germinoma has a 5-year survival rate of 90–95% or more and is among the intracranial tumors with the best prognosis. With the introduction of combined chemoradiation therapy, long-term neurocognitive function has improved compared with radiation alone. However, even after cure, endocrine sequelae of radiation therapy (growth hormone deficiency, hypothyroidism, hypogonadism, persistent diabetes insipidus) may remain permanently in a considerable number of patients. Pineocytoma (WHO grade I–II) has a good 5-year survival rate of 80–90% or more with complete resection. In contrast, pineoblastoma often already has cerebrospinal fluid dissemination at the time of diagnosis, so its 5-year survival rate remains at about 50–60%, and the risk of recurrence is high. The prognosis of non-germinomatous germ cell tumors varies greatly by histological type; mature teratoma is curable, but yolk sac tumor and embryonal carcinoma have a poor prognosis.
In pediatric patients who have received cranial radiation therapy, endocrine sequelae appear in proportion to the radiation dose; growth hormone deficiency is the most common and develops within a few years after treatment. In addition, thyroid-stimulating hormone (TSH) deficiency, adrenocorticotropic hormone (ACTH) deficiency, and hypogonadism may occur. These sequelae are determined by the radiation field (craniospinal vs whole-brain vs local) and total dose. Diabetes insipidus often persists after treatment, requiring long-term desmopressin treatment. Neurocognitive decline (reduced memory, concentration, and processing speed) is also a major long-term sequela after radiation therapy, requiring regular neuropsychological evaluation and rehabilitation education.
Most pineal tumors are sporadic and their causes are unclear, so primary prevention is difficult. In hereditary forms (trilateral retinoblastoma due to RB1 variants, DICER1 variant-associated pineoblastoma), early detection can be pursued through genetic counseling and regular brain imaging surveillance of carrier family members. Minimizing nighttime light exposure helps maintain melatonin secretion, and reducing unnecessary nighttime use of electronic devices (blue light exposure) is recommended.
Secondary prevention focuses on early detection through immediate imaging diagnosis and tumor marker testing at early symptoms such as precocious puberty, diabetes insipidus, headache, and visual disturbances. After treatment of pineal tumors, regular brain MRI for recurrence surveillance (every 3–6 months for the first 2 years, then every 6–12 months), measurement of serum βhCG/AFP, regular evaluation of endocrine function (growth hormone, thyroid, adrenal, gonadal function), and neurocognitive evaluation are needed. For tertiary prevention, a comprehensive long-term follow-up system is established, including growth hormone replacement after radiation therapy, thyroid hormone replacement, rehabilitation education, and psychosocial support.